Welcome to our dedicated page for Myomo SEC filings (Ticker: MYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myomo, Inc. (NYSE American: MYO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Myomo is a wearable medical robotics company that develops and markets MyoPro myoelectric orthoses for individuals with neuromuscular disorders and upper-limb paralysis, and its filings offer detailed insight into how this business is structured and financed.
Through documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, Myomo reports information on revenue from MyoPro devices, gross margin, operating expenses, cash position and risk factors related to reimbursement, financing, product development and regulatory approvals. These filings also describe the company’s focus on its MyoPro product line, its relationships with orthotics and prosthetics providers and the Veterans Health Administration, and its dependence on third-party payers such as Medicare Part B and private insurers.
Current reports on Form 8-K document specific material events. For example, Myomo has filed 8-Ks describing a Loan and Security Agreement that provides term loans secured by a lien on the company’s assets, including intellectual property, together with associated warrants to purchase common stock and potential conversion rights. Another 8-K outlines a salary-for-restricted stock units program for certain executives. These filings explain key terms such as interest-only periods, maturity dates, financial covenants and equity-related features.
On Stock Titan, users can view these filings as they are made available from EDGAR and use AI-powered summaries to understand complex sections, including capital structure provisions, debt covenants, warrant terms and equity compensation arrangements. The page also surfaces Form 4 and other ownership-related filings, helping users monitor insider transactions and changes in beneficial ownership alongside the company’s broader financial and operational disclosures.
FEBBO WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. director William J. Febbo received an equity award covering 45,000 shares of Common Stock as compensation. The Form 4 shows this as a grant of restricted stock units under the company’s 2018 Stock Option and Incentive Plan, with no cash paid per share.
The RSUs vest in full on the first anniversary of the grant date, meaning the entire 45,000-unit award is scheduled to vest after one year if conditions are met. Following this award, Febbo reports beneficial ownership of 45,000 shares/units directly, reflecting a routine, compensation-related equity grant rather than an open‑market purchase or sale.
MYOMO, INC. director William J. Febbo filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing does not report any stock transactions or holdings, indicating it is primarily an administrative disclosure of his insider status.
Myomo, Inc. appointed William “Will” Febbo to its Board of Directors effective April 14, 2026, as a Class II director serving until the 2028 annual meeting, bringing over 30 years of experience in healthcare, financial services, and technology-driven businesses.
As a non-employee director, he was granted 45,000 restricted stock units (RSUs) that vest on the first anniversary of his appointment. He will also receive an annual cash retainer of $60,000 and an additional $85,000 per year in RSUs vesting quarterly. The company highlighted his prior leadership at OptimizeRx, where revenue expanded from $5 million to $92 million with a five-year CAGR of 41%, and his capital markets background as important additions to Myomo’s board.
GUDONIS PAUL R reported acquisition or exercise transactions in this Form 4 filing.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis received a grant of 16,666 shares of Common Stock in the form of Restricted Stock Units (RSUs). This award comes under a program allowing employees to forego 10% of their salary for three months in exchange for RSUs with a grant date fair value equal to 115% of the salary exchanged. The RSUs vest in full on July 9, 2026. After this grant, Gudonis directly holds 1,277,316 shares of the company’s common stock.
MYOMO, INC. Chief Financial Officer David A. Henry reported routine equity compensation and related tax withholding transactions in company stock. He received 12,500 Restricted Stock Units under a board-approved program where employees exchange 10% of three months of salary for RSUs valued at 115% of the salary given up. These RSUs vest in full on July 9, 2026. On April 13, 2026, 3,953 shares of common stock at $0.71 per share were disposed of solely to pay income taxes on restricted stock units that vested on April 12, 2026, pursuant to an irrevocable election made on December 11, 2025. Following these transactions, he directly holds 445,174 shares of Myomo common stock.
MYOMO, INC. reported that Chief Executive Officer Paul R. Gudonis acquired 19,395 shares of common stock through a grant of Restricted Stock Units (RSUs) with no cash paid per share. These RSUs were issued under a program allowing employees to exchange 10% of their salary for equity at a grant date fair value of 115% of the salary given up, covering three months of salary.
The RSUs from this grant vest in full on July 9, 2026. After this award, Gudonis directly holds a total of 1,280,045 shares of Myomo common stock, underscoring that this is primarily a compensation-related equity grant rather than an open‑market purchase.
MYOMO, INC. director Heather C Getz reported an open-market purchase of company stock. On March 16, 2026, she bought 20,000 shares of Myomo common stock at $0.6986 per share, in a single open-market transaction. Following this trade, her direct ownership increased to 131,754 shares of common stock.
MYOMO, INC. director Kirk Thomas F reported an open-market purchase of 72,000 shares of Common Stock. The weighted average purchase price was about $0.7099 per share, with individual trade prices ranging from $0.70 to $0.71. Following these purchases, he directly owns 553,857 shares.
MYOMO, INC. director Heather C. Getz made an open-market purchase of 70,000 shares of common stock at a weighted average price of $0.728 per share. The trades were executed in multiple lots between $0.72 and $0.73 per share.
Following this transaction, she directly owns 111,754 shares of MYOMO common stock. The filing describes these transactions as open-market purchases, indicating she used personal capital to increase her direct equity position in the company.